Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 7
2012 2
2013 8
2014 6
2015 2
2016 2
2017 3
2018 3
2019 2
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Saxagliptin / Metformin (New Therapeutic Indication) -- Benefit Assessment According to 35a Social Code Book V.
Institute for Quality and Efficiency in Health Care. Institute for Quality and Efficiency in Health Care. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Jun 27. Extract of Dossier Assessment No. A13-12. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Jun 27. Extract of Dossier Assessment No. A13-12. PMID: 27905755 Free Books & Documents. Review.
For this new therapeutic indication, the company only requested consultation on the appropriate comparator therapy (ACT) for the individual substance saxagliptin, but not for saxagliptin / metformin. The Federal Joint Committee (G-BA) specified the following ACT for …
For this new therapeutic indication, the company only requested consultation on the appropriate comparator therapy (ACT) for the individual …
Saxagliptin / Metformin -- Benefit Assessment According to 35a Social Code Book V.
Institute for Quality and Efficiency in Health Care. Institute for Quality and Efficiency in Health Care. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Feb 13. Extract of Dossier Assessment No. A12-16. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Feb 13. Extract of Dossier Assessment No. A12-16. PMID: 28609031 Free Books & Documents. Review.
Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
Fonseca V, Zhu T, Karyekar C, Hirshberg B. Fonseca V, et al. Diabetes Obes Metab. 2012 Apr;14(4):365-71. doi: 10.1111/j.1463-1326.2011.01553.x. Epub 2012 Jan 18. Diabetes Obes Metab. 2012. PMID: 22192246 Clinical Trial.

RESULTS: At week 18, the adjusted mean reduction from baseline HbA1c was -0.88% for saxagliptin + metformin XR and -0.35% for uptitrated metformin XR (difference, -0.52%; p < 0.0001). ...More patients achieved HbA1c <7.0% with saxagliptin + metformin

…
RESULTS: At week 18, the adjusted mean reduction from baseline HbA1c was -0.88% for saxagliptin + metformin XR and -0.35% for …
Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2017 Mar;77(3):319-330. doi: 10.1007/s40265-017-0697-1. Drugs. 2017. PMID: 28176222 Review.
In three phase III trials, saxagliptin + dapagliflozin + metformin was more effective at providing glycaemic control than saxagliptin + metformin or dapagliflozin + metformin in previously treated patients with T2DM and inadequate glycaemic control on metformin mono …
In three phase III trials, saxagliptin + dapagliflozin + metformin was more effective at providing glycaemic control than saxagliptin …
Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia.
Mintz ML, Minervini G. Mintz ML, et al. Curr Med Res Opin. 2014 May;30(5):761-70. doi: 10.1185/03007995.2014.880674. Epub 2014 Jan 30. Curr Med Res Opin. 2014. PMID: 24397584 Clinical Trial.
Hypoglycemia with saxagliptin + metformin and glipizide + metformin was reported by 15 (24 events) and 165 (896 events) patients, respectively, through week 104. The mean (SD) number of hypoglycemic events per patient reporting hypoglycemia was lower with saxagli …
Hypoglycemia with saxagliptin + metformin and glipizide + metformin was reported by 15 (24 events) and 165 (896 events) patien …
Addendum to Commission A12-16 (Saxagliptin / Metformin).
Institute for Quality and Efficiency in Health Care. Institute for Quality and Efficiency in Health Care. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Apr 12. Extract of Dossier Assessment No. A13-14. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Apr 12. Extract of Dossier Assessment No. A13-14. PMID: 28609039 Free Books & Documents. Review.
The commission of the G-BA for the assessment of these 2 studies reads as follows: "In this context the data should be assessed with regard to the question as to whether the studies and analyses submitted by the company for saxagliptin / metformin versus glimepiride …
The commission of the G-BA for the assessment of these 2 studies reads as follows: "In this context the data should be assessed with regard …
Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia.
Bekele M, Norheim OF, Hailu A. Bekele M, et al. MDM Policy Pract. 2021 Apr 27;6(1):23814683211005771. doi: 10.1177/23814683211005771. eCollection 2021 Jan-Jun. MDM Policy Pract. 2021. PMID: 34104781 Free PMC article.
The annual unit cost per patient was US$70 for metformin, US$75 for metformin + glibenclamide, and US$309 for metformin + saxagliptin. The ICER for saxagliptin + metformin was US$2259 per DALY averted. The ICER results were sensitive to various changes in cost, effe …
The annual unit cost per patient was US$70 for metformin, US$75 for metformin + glibenclamide, and US$309 for metformin + saxagliptin. The I …
Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures.
Neutel JM, Zhao C, Karyekar CS. Neutel JM, et al. Diabetes Ther. 2013 Dec;4(2):269-83. doi: 10.1007/s13300-013-0028-9. Epub 2013 Jul 24. Diabetes Ther. 2013. PMID: 23881432 Free PMC article.
RESULTS: At week 4, the adjusted mean SE change from baseline in 24-h MWG was -19.0 5.7 mg/dL (95% CI -30.3 to -7.6) for saxagliptin + metformin XR and -8.2 6.0 mg/dL (95% CI -20.0 to 3.7) for uptitrated metformin XR. Mean changes from baseline in 2-h PPG and FPG we …
RESULTS: At week 4, the adjusted mean SE change from baseline in 24-h MWG was -19.0 5.7 mg/dL (95% CI -30.3 to -7.6) for saxagliptin …
38 results